[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ionis Pharmaceuticals, Inc. Common Stock (IONS)
Metagenomi will present preclinical data supporting a new collaboration target with Ionis Pharmaceuticals at an upcoming Nature Conference. This news highlights ongoing research and potential future developments for Ionis.
About Ionis Pharmaceuticals, Inc. Common Stock
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA-targeted therapeutics.
Ionis Pharmaceuticals, Inc. Common Stock uses the ticker $IONS for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Ionis Pharmaceuticals, Inc. Common Stock (IONS) trading volume is up XXXXXX% from the previous X months.
- Ionis Pharmaceuticals, Inc. Common Stock (IONS) social dominance is up XXXXXX% from the previous week.
- Ionis Pharmaceuticals, Inc. Common Stock (IONS) sentiment is up XXXXX% from the previous month.
Price: $XXXXX
Price 24-Hour Time-Series Raw Data
The stock price is experiencing a significant surge, hitting a 52-week high, driven by positive analyst sentiment, strong Q3 earnings, and promising Phase X trial results for key drugs. This positive momentum is outweighing a minor FDA hold, and social media sentiment is overwhelmingly positive.
24-Hour: XXXX% 7-Day: -XXX% 30-Day: XXX%
1-Year High: $XXXXX on 2025-11-28
1-Year Low: $XXXXX on 2025-04-08
AltRank: XXX
AltRank 24-Hour Time-Series Raw Data
Ionis Pharmaceuticals, Inc. Common Stock (IONS) is currently AltRank #896 based on combined combined social and market metrics
Daily Average: XXX
X Week: XXX +32
X Month: XXX -XXX
X Months: XXX +145
X Year: XXX -XX
1-Year High: XXXXX on 2025-08-06
1-Year Low: XX on 2025-01-11
Galaxy Score: XXXXX
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -X
X Month: XX +13
X Months: XX -X
X Year: XX +18
1-Year High: XX on 2025-04-07
1-Year Low: XX on 2025-07-08
Engagements: XXXXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXXXXX
X Week: XXXXXX -XX%
X Month: XXXXXXX +8.20%
X Months: XXXXXXXXX +29%
X Year: XXXXXXXXX +122%
1-Year High: XXXXXXX on 2025-02-19
1-Year Low: XXXXX on 2025-03-09
Engagements by network (24h): News: XX Reddit: X X: XXXXX YouTube: XXXXX
Mentions: XXX (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXX
X Week: XXX -XX%
X Month: XXXXX +46%
X Months: XXXXX +83%
X Year: XXXXX +161%
1-Year High: XXX on 2025-09-03
1-Year Low: XX on 2025-01-27
Mentions by network (24h): News: X Reddit: X X: XXX YouTube: XX
Creators: XX (24h)
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Ionis Pharmaceuticals, Inc. Common Stock (IONS) in the last XX hours which is up XXXX% from XX in the previous XX hours
Daily Average: XX
X Week: XXX -XX%
X Month: XXX +25%
X Months: XXXXX +153%
X Year: XXXXX +182%
1-Year High: XXX on 2025-06-28
1-Year Low: XX on 2025-01-28
The most influential creators that mention Ionis Pharmaceuticals, Inc. Common Stock in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @pikva63 | X | X | X | XXX |
| @RNAiAnalyst | X | XXXXXX | X | XXX |
| @Quantumup1 | X | XXXXX | X | XXX |
| @ArtsStocks | X | XXX | X | XXX |
| @SteveDJacobs | X | XXXXX | XX | XXX |
| @MacroSkokie | X | XXXXX | X | XX |
| @fundmyfund | X | XXXXX | X | XX |
| @ionispharma | X | XXXXX | X | XX |
| @BuyTheUgly | X | XX | X | XX |
| @john_steel70462 | XX | XXX | X | XX |
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% +12%
X Month: XX% +21%
X Months: XX% +14%
X Year: XX% +25%
1-Year High: XXX% on 2025-01-30
1-Year Low: XX% on 2025-01-26
Most Supportive Themes:
- Analyst Upgrades and Price Targets: (30%) Analysts are increasing their confidence and price targets for Ionis Pharmaceuticals.
- Positive Phase X Trial Results: (25%) Promising results from Phase X trials for olezarsen and zilganersen are leading to planned regulatory filings.
- Strong Q3 Earnings Report: (20%) Ionis Pharmaceuticals reported strong Q3 earnings, exceeding expectations and raising its full-year revenue outlook.
- 52-Week High Stock Price: (15%) The stock has reached a 52-week high, reflecting positive market sentiment and strong community engagement.
Most Critical Themes:
- FDA Holds on Drug Testing: (5%) The FDA has placed a hold on certain drug testing, which could potentially delay study readouts and impact investor sentiment.
Social Dominance: XXXXX%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: XXXXX%
X Week: XXXXX% +0.04%
X Month: XXXX% +0.0057%
X Months: XXXX% +0.01%
X Year: XXXX% +0.0027%
1-Year High: XXXXX% on 2024-12-22
1-Year Low: XXXXXX% on 2025-10-24
Market Dominance: XXXXX%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-12-02
1-Year Low: XXXXXXX% on 2025-04-02
Market Cap: $XXXXXXXXXXXXXX
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXXX -$3.30%
X Month: $XXXXXXXXXXXXXX +$9.20%
X Months: $XXXXXXXXXXXXXX +$126%
X Year: $XXXXXXXXXXXXXX +$114%
1-Year High: $XXXXXXXXXXXXXX on 2025-11-28
1-Year Low: $XXXXXXXXXXXXX on 2025-04-08
Top Ionis Pharmaceuticals, Inc. Common Stock News
Top news links shared on social in the last XX hours
Showing a maximum of X news posts for non-authenticated requests. Use your API key in requests for full results.
"Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference"
News Link @YahooFinance 2025-12-01T13:37Z 228.6M followers, 3031 engagements
Top Ionis Pharmaceuticals, Inc. Common Stock Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Meet Justin Dhindsa MCAT Tutor at Inspira Advantage"
YouTube Link @inspiraadvantage 2025-12-11T16:56Z 2090 followers, XX engagements
"Cowen Named $IONS a 2026 Best Idea reiterated at a Buy a $XX PT and Best Ideas 2026: New Launches And Key Pipeline Catalysts To Drive Upside $TAK $BCRX $NVS $biib $azn $nvo $lly $arwr We see robust sales growth in FY26 driven by #Tryngolza in sHTG #Dawnzera zilganersen and"
X Link @ArtsStocks 2025-12-11T15:12Z XXX followers, XXX engagements
"$IONS Guys Don't miss the next move in a few hours. 💸🔜"
X Link @Trade_market120 2025-12-11T13:40Z XX followers, XX engagements
"RBC Capital $ARWR's PT to $XX from $XX and reiterated at an Outperform rating. $IONS $WVE RBC Capital saidWe hosted a 3-day NDR in the Midwest with CEO CMO and IR. On APOC3 recent approval of Redemplo marks a key milestone for the organization (first approved drug) and the company remains upbeat about early commercial traction. On sHTG management came across as confident that the drug can hit APs in SHASTA-3/4 next year given: 1) IONS hit the stats convincingly 2) baseline characteristics are comparable and 3) recent changes to study design should boost event rate. Overall continues to see a"
X Link @Quantumup1 2025-12-11T12:44Z 3926 followers, 1864 engagements